Tetrodotoxin for Neuropathic&Cancer Pain Relief: History
Please note this is an old version of this entry, which may differ significantly from the current revision.

Tetrodotoxin (TTX) is a potent neurotoxin found mainly in puffer fish and other marine and terrestrial animals. TTX blocks voltage-gated sodium channels (VGSCs) which are typically classified as TTX-sensitive or TTX-resistant channels. VGSCs play a key role in pain signaling and some TTX-sensitive VGSCs are highly expressed by adult primary sensory neurons. During pathological pain conditions, such as neuropathic pain, upregulation of some TTX-sensitive VGSCs, including the massive re-expression of the embryonic VGSC subtype NaV1.3 in adult primary sensory neurons, contribute to painful hypersensitization. In addition, people with loss-of-function mutations in the VGSC subtype NaV1.7 present congenital insensitive to pain. TTX displays a prominent analgesic effect in several models of neuropathic pain in rodents. According to this promising preclinical evidence, TTX is currently under clinical development for chemo-therapy-induced neuropathic pain and cancer-related pain.

  • tetrodotoxin
  • TTX
  • voltage-gated sodium channels
  • neuropathic pain
  • cancer pain

1. Introduction

Chronic pain is a serious public health and socioeconomic problem that affects millions of people worldwide each year [1]. Some chronic pain conditions can be a consequence of abnormal functioning of the nervous system. In particular, neuropathic pain arises from a lesion or disease of the somatosensory system at peripheral or central level [2]. Peripheral neuropathic pain is the result of injuries to the peripheral nervous system induced by various conditions, including metabolic diseases, infections, mechanical trauma, and chemotherapy [3]. Central neuropathic pain involves injuries to the central nervous system, commonly caused by spinal cord injury, stroke, and multiple sclerosis [4]. The initial lesions involved in both forms of neuropathic pain trigger a cascade of changes that lead to maladaptive plasticity within the nervous system and inevitably to neuropathic hypersensitivity [5]. The prevalence of chronic pain with neuropathic characteristics has been estimated to be in the range of 7–10% [6] and it is expected to rise in the future [3].
Cancer-related pain is a very invalidating symptom, affecting approximately 66% of patients who suffer from cancer [7]. Cancer-related pain frequently presents a mixed pathophysiology, including both nociceptive and neuropathic components, depending on the progression and extension of tumor, being often very difficult to differentiate between acute and chronic pain [8].
Commonly used analgesics for nociceptive pain, such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, are less effective in neuropathic [9] or cancer pain [10]. In fact, among cancer patients, those with cancer-related neuropathic pain usually have more trouble to optimally control pain [11]. First-line drug therapies for neuropathic pain include tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentinoids, and topical application of lidocaine or capsaicin [12]. These medications can be effective, but carry the potential risk of many side effects [12]. Opioids are lower-line drug options for neuropathic pain, as there is low evidence to support the use of opioids for long-term in chronic neuropathic pain, with possible benefit only for short-term use [9][13]. Therefore, despite the multiple agents available for the treatment of neuropathic pain, current treatment options provide an average reduction of neuropathic pain by 30–50% [9]. The effectiveness of available drugs in the treatment of cancer pain is also very low [14]. The difficulty in optimally treating these pain conditions has prompted significant research into new analgesic agents with fewer side effects.
Tetrodotoxin (TTX) is a potent non-peptide guanidinium neurotoxin that blocks voltage-gated sodium channels (VGSCs) found in puffer fish and other marine and terrestrial animals [15]. VGSCs play an important role in pain and, in particular, numerous studies have shown that some of the TTX-sensitive VGSC subtypes are strongly implicated in the pathophysiology of chronic pain, especially neuropathic pain [16]. Since TTX blocks this subset of VGSCs in a highly selective manner, this agent may have a potential role in relieving neuropathic pain. In fact, this agent is progressing in its preclinical and clinical development, having been evaluated in various clinical trials for the indications of cancer-related pain (NCT00725114, NCT00726011) and chemotherapy-induced neuropathic pain (NCT01655823).

2. Role of TTX-Sensitive Voltage-Gated Sodium Channels (VGSCs) in Neuropathic and Cancer Pain

The VGSCs are integral membrane proteins composed of a 260 kDa α-subunit and one or more β-subunits, being the α-subunit responsible for forming the pore and for the main biophysical properties of the channel [16]. Most VGSCs are located at peripheral and/or central nervous system (see Figure 1), and are responsible for generating the Na+ currents that lead to the initiation and propagation of neuronal action potentials [17]. TTX binds to VGSCs by the interaction between the positively charged guanidine group in the TTX molecule with the negatively charged carboxylate residues that are placed around the outer vestibule of the channel; this binding occludes the channel pore and blocks Na+ current [18]. VGSCs are classified according to its sensitivity to TTX. Thus, TTX-sensitive VGSCs (NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.6 and NaV1.7) are blocked by nanomolar concentrations of this neurotoxin, whereas TTX-resistant VGSCs (NaV1.5, NaV1.8, NaV1.9) are inhibited at micromolar concentrations [16]. The mechanism of action by which TTX exerts its analgesic effect is by binding to the α-subunit within the outer vestibule of the VGSC, blocking the entry of Na+ ions through the channel [16][18]. In this manner, TTX reduces the Na+ ionic fluxes required for the initiation and conduction of nerve impulses.
Figure 1. Main location of voltage specific sodium channels in the nervous system.
Nociceptive pain has a physiological protective role in preventing tissue injury. Under normal conditions, primary nociceptive neurons generate action potentials only when they are stimulated with a noxious stimulus [5]. Following nerve injury, nociceptive neurons can begin to discharge spontaneously in an abnormal way, and they reduce their response threshold and increase their discharge frequency, evoked by stimulation. These processes are responsible for inducing hyperexcitability of primary sensory neurons (peripheral sensitization) [5]. In addition, ongoing abnormal activity originating in injured peripheral nerves can be the trigger of central sensitization [19]. Peripheral and central mechanisms, occurring sequentially and concurrently, are responsible for the induction and maintenance of neuropathic pain [5].
VGSCs play a role in persistent and chronic pain as it has been reported that changes on VGSC expression in primary sensory neurons, their abnormal accumulation at the site of injury, as well as posttranslational modifications of these channels, occur after nerve injury, and lead to peripheral sensitization processes [20] (see Table 1).
Table 1. Implication of TTX-sensitive voltage-gated sodium channels in neuropathic pain.
Channel Normal Localization [16] Changes of Expression in Pain States
NaV1.1 -CNS, PNS-Microglia -Unclear after PNI in NP [16]
NaV1.2 -CNS, very low expression in PNS-SC in lamina I/II -Unclear after PNI in NP [16]
NaV1.3 -Negligible in DRG (embryonic isoform)-SC in lamina I/II Upregulated in DRG: CCI [21], PDN [22][23],
SNI [24][25], SNL [26][27],
traumatic nerve injury (human) [28]
Upregulate in painful neuromas (human): [29]
Trigeminal ganglion: trigeminal neuropathic pain [30][31][32]
Upregulated in sciatic nerve: PDN [33]
Upregulated in spinal cord: SCI [34]
NaV1.4 -Skeletal muscle  
NaV1.6 -Nodes of Ranvier-SC-PNS-Epidermal free nerve terminals-keratinocytes-Microglia Upregulated in DRG: PDN [35],
lumbar 5 ventral root transection [36],
CINP (oxaliplatin) [37]
Upregulated in sciatic nerve: CCI [38]
Upregulated trigeminal ganglion: trigeminal neuropathic pain [30]
NaV1.7 -PNS in all types of DRG neurons-SC-Epidermal free nerve terminals Downregulated in DRG: SNL [39], SNI [24][25],
traumatic nerve injury (human) [28]
Upregulated in DRG: CCI [40], SNI [41], SNL [27],
CINP (paclitaxel) [42],
cancer-related pain (humans) [42],
Herpesvirus quiescent infection [43],
painful neuromas (human) [34]
Upregulated in spinal cord: CINP (paclitaxel) [42]
Upregulated trigeminal ganglion: trigeminal neuropathic pain [44]
Upregulated in sciatic nerve: CCI [45]
Thus, it has been shown a massive upregulation of the expression of the TTX-sensitive VGSC NaV1.3 in peripheral sensory neurons following nerve injury, in several models of neuropathic pain in rodents [21][23][24][26][33], as well as in patients [28][29]. NaV1.3 subtype might account for neuronal hyperresponsiveness during neuropathic pain as this isoform is not expressed in peripheral sensory neurons in normal condition (only during embryonic development) [20], but as mentioned before, it dramatically upregulates following nerve injury in animals and patients with neuropathic pain (see Table 1). However, specific reduction in the expression of NaV1.3 subtype alone (with intrathecal administration of antisense oligonucleotides or with knockout mice), is not sufficient to reduce behavioral hypersensitivity associated with nerve injury [46][47].
Another TTX-sensitive VGSC that has received much attention is NaV1.7 subtype. This VGSC is predominantly localized in the peripheral nervous system, and many studies have reported a strong correlation between NaV1.7 function and many pain states in rodents and humans [20]. However, the role of NaV1.7 in neuropathic pain remains uncertain, as contradictory results have been reported in rodents and humans, with some studies showing upregulation [27][34][40][41][45], and others downregulation [24][28][39] in primary sensory neurons. In addition, mice lacking NaV1.7 normally developed neuropathic pain after peripheral nerve injury [48]. Interestingly, it has been shown that NaV1.7 could have a more relevant role in the somatosensory system of humans than that of mice, since NaV1.7 is the predominant VGSC in human dorsal root ganglia (DRG) (50% of total VGSC expression), whereas in mice, this subtype represents only a small percentage (18% of total VGSC expression) [49]. In addition, in the same study, it is shown that human DRG neurons in primary cultures treated with paclitaxel (an antitumor drug which is known to induce neuropathic pain), increase the expression of NaV1.7 [49]. Finally, the importance of NaV1.7 for pain in humans is revealed by the existence of loss-of-function mutations of NaV1.7 gene (SCN9A) that lead to congenital insensitivity to pain, and gain-of-function mutations of this gene, which lead to congenital pain disorders characterized by hyperexcitability and extreme pain [50].
More recently, it has been shown that NaV1.6 also plays a relevant role in neuropathic pain of different etiologies, as several studies have reported that NaV1.6 is upregulated during neuropathic pain of different etiologies [35][36][37][38]. In addition, specific inhibition of NaV1.6 with small interfering RNA injected into the DRG [51], or knockout mice [52], reduce neuropathic pain in rodents. On the other hand, the involvement in neuropathic pain of other TTX-sensitive VGSCs present in the nervous system (NaV1.1 and NaV1.2) is not totally clear [16].
TTX-resistant VGSCs which are preferentially expressed in primary afferent neurons (NaV1.8 and NaV1.9) are involved in some pain conditions [20]. However, the role of these VGSC subtypes in neuropathic pain is also unclear since it has been described that they are downregulated in DRG after nerve injury [23][24][53][54]. In addition, experiments with knockout mice show a role of NaV1.9, and to a lesser extent or NaV1.8 in the generation of cold hypersensitivity, but not mechanical hypersensitivity in models of neuropathic pain [55]. On the other hand, the principal cardiac VGSC NaV1.5 is not involved in pain [17], but it is of particular interest, as any VGSC blocker with analgesic potential, should not inhibit NaV1.5 at therapeutic doses, for obvious safety reasons. Interestingly, NaV1.5 is considered a TTX-resistant VGSC [56].

3. Effects of TTX in Preclinical Models of Neuropathic and Cancer Pain

3.1. Preclinical Studies on Neuropathic Pain

TTX has been widely employed in vitro to characterize the role of VGSCs in nociception and chronic pain. In addition, the effects of TTX on pain behaviors have been studied in several models of acute and chronic pain. Thus, the systemic administration of TTX has shown analgesic effect in classical pain models such as in the writhing test in mice [57] and rats [58], and in the formalin test in rats [57]. In another study, systemic TTX showed a significant reduction of mechanical hyperalgesia in a rat model of inflammatory pain induced by intraplantar carrageenan [59]. Our group demonstrated that the systemic administration of TTX reduced pain behaviors in different models of visceral pain in mice [60].
As we have described in the previous section, some TTX-sensitive VGSCs play a key role in neuropathic pain, and this probably explains why the effect of TTX has been more widely tested in preclinical models of neuropathic pain (see Table 2).
Table 2. Summary of the effects of TTX on pain studies in laboratory animals.
Administration of TTX TTX Doses Effect (None, Moderate, Strong) Pain Test Pain Model Reference
Sciatic nerve blockade TTX osmotic pump Strong MA, TH SNI and CCI [61]
Topical DRG 12.5–50 nM/5 µL Strong (12.5–50 µg) MA SNL [62]
Epidural 25 nM/5 µL Strong (25 µg) MA SNL [62]
Topical median nerve Gel pads with TTX Strong MA CCI [63]
Intraperitoneal 25 nM/5 µL None MA SNL [62]
8 µg None MA CINP (vincristine) [64]
Subcutaneous 1–6 µg Strong MA, TH, CA CINP (paclitaxel) [65]
6 µg Strong MA intraplantar capsaicin [66]
0.3–6 µg Strong (1–6 µg) MA, TH SNL [57]
Acute and subchronic TTX (1–6 µg) Strong MA, TH CCI [67]
Acute and subchronic TTX (1–6 µg) Moderate MA, TH CCI-intraorbital nerve [67]
8 µg Strong MA, TH burn-induced pain [68]
Intragastrical 5–20 µg Strong MA, TH Postherpetic Neuralgia (RTX) [69]
Intramuscular Acute and subchronic TTX (1–6 µg s.c.) Strong MA Postherpetic Neuralgia (RTX) [69]
0.03–1 ug Moderate MH CINP (oxaliplatin) [70]
Intrathecal 10 µg Strong MA, TH bone cancer pain [71]
Lyu and collaborators [62] reported the first study on TTX effects in a model of neuropathic pain in 2000. These authors showed that mechanical allodynia induced by spinal nerve ligation (SNL) was significantly attenuated by the topical application to the DRG of TTX at low doses that did not block action potential conduction. This study also reported that TTX ameliorates mechanical hypersensitivity when applied to the epidural space but not when this neurotoxin was administered intraperitoneally, suggesting a local effect of TTX. However, the dose of TTX used in this study (25 nM) was probably too low to achieve a systemic analgesic effect. In a later study was reported that the nerve blockade with TTX immediately following nerve injury, prevented the development of thermal and mechanical hypersensitivity, and the spontaneous afferent activity, in two rat models of neuropathic pain, the chronic constrictive injury (CCI) and the spared nerve injury (SNI) models [61]. However, when nerve blockade was performed once the neuropathic pain was established (10 days after nerve injury), it only transiently inhibited mechanical hypersensitivity in both neuropathic pain models, suggesting that the local inhibition of TTX-sensitive VGSCs during the initial stage of neuropathic pain might be sufficient to inhibit the subsequent development of neuropathic pain [61]. Another report showed that the preventive local application of TTX onto the median nerve inhibited the development of tactile allodynia subsequent to the chronic constriction injury of this nerve, in parallel with a reduction of the increase of astrocyte activation in the cuneate nucleus [63].
Two independent studies evaluated the effects of systemic administration of TTX in neuropathic pain models induced by surgical nerve damage. Marcil and collaborators [57] tested the ameliorative effects of several doses of subcutaneous TTX on pain-like behaviors induced by the partial sciatic nerve ligation (pSNL) model in rats and compared such effects with those produced by morphine. They found that TTX reduced mechanical allodynia and thermal hyperalgesia, without affecting the contralateral non-injured side. In contrast, the administration of morphine reduced neuropathic pain, but it also led to an increase in pain threshold strikingly above preoperative values in both ipsilateral and contralateral paws, although the dose of morphine was probably too high. In another report, it was shown that acute and subchronic subcutaneous treatment with TTX suppressed mechanical and thermal hyperalgesia and mechanical allodynia in the rat CCI model [67]. In the same study, the authors evaluated the effects of subcutaneous TTX on pain behaviors induced by the CCI of the infraorbital nerve in rats, and found that TTX had only modest analgesic effects in this pain condition. They also provided data about the possible mechanisms that contribute to the ameliorative effects of TTX in neuropathic pain. In particular, they showed that acute subcutaneous administration of TTX attenuated the increase of c-Fos expression (widely used as marker of neuronal activity) in the dorsal horn of the spinal cord and in some supraspinal areas in response to light mechanical stimulation of the ipsilateral hind paw. In addition, they found that TTX alleviated pain-related behaviors induced by nerve injury through mechanisms that might involve complex interactions with opioidergic systems, whereas noradrenergic and serotoninergic systems were not involved [67].
TTX was also evaluated in several models of cancer chemotherapy-induced neuropathic pain with contradictory results. Thus, the intraperitoneal administration of TTX did not attenuate mechanical allodynia induced by vincristine in rats, whereas other drugs including morphine, pregabalin, mexiletine and lidocaine did [64]. In a more recent study, Alvarez and Levine [70] showed that intramuscular TTX produced a small but significant reduction of neuropathic muscle pain induced by the antineoplastic agent oxaliplatin in rats. Our group found that acute TTX administered subcutaneously attenuated mechanical and cold allodynia and heat hyperalgesia induced by paclitaxel in mice, once the neuropathy was already established [65]. In addition, we also showed that the preventative administration of TTX completely prevented the development of mechanical and cold allodynia, without affecting heat hyperalgesia. Such findings open the possibility of preventative treatment of neuropathic pain induced by chemotherapy in patients, where the moment of onset of the nerve insult is known and preventive treatment could be possible. The mechanism by which TTX prevents chemotherapy-induced neuropathic pain is unknown. However, it has been shown that chemotherapy-induced neuropathy is associated with upregulation of some TTX-sensitive VGSCs in the DRG and in the spinal cord (see Table 2). It is possible to speculate that blockade of the early spontaneous afferent activity generated by the upregulation of TTX-sensitive VGSCs during the development of chemotherapy-induced neuropathic pain explains the preventive effect of TTX. A similar mechanism has been shown in other models of neuropathic pain [61]. On the other hand, the discrepancies between the results obtained by TTX in the models of neuropathic pain induced by three different chemotherapeutic agents may be attributable to the different underlying mechanisms by which these anticancer drugs induce neuropathic pain [72].
Other studies evaluated the effects of systemic administration of TTX in preclinical models of neuropathic pain of different etiologies other than those induced by a surgical lesion or chemotherapy. Thus, the subcutaneous administration of TTX suppressed thermal hyperalgesia and mechanical allodynia in a rat full burn wound pain model. Interestingly, the results of this study indicated that TTX reduced thermal hyperalgesia more effectively than morphine, whereas both drugs showed similar effects reducing mechanical allodynia [68]. More recently, the effects of oral administration of TTX pellets have been evaluated in a rat model of postherpetic neuralgia [69]. In this study, intragastric treatment with TTX was able to reduce mechanical allodynia in a similar way than oral pregabalin. In addition, these authors also showed that the intramuscular administration with TTX reduced mechanical allodynia at doses significantly lower than those used during the oral treatments. However, they claimed the TTX pellets described in this article might have a higher therapeutic window than the intramuscular administration of TTX (used in patients). It would be interesting to evaluate this new pharmaceutical form of TTX in more widely used models of neuropathic pain than the unusual model of postherpetic neuralgia induced by resiniferatoxin (RTX). Finally, our group reported that TTX inhibited capsaicin-induced mechanical hypersensitivity in mice [66], which is considered a surrogate model of neuropathic pain [73].
In summary, the systemic or local treatment with TTX has shown efficacy in reducing pain-like behaviors in several animal models of neuropathic pain of different etiology. There is only one study that, by using an adequate systemic dose of TTX, failed to inhibit neuropathic pain in rodents [64]. Therefore, these findings point to the therapeutic usefulness of TTX in neuropathic pain and support the key role that TTX-sensitive VGSCs play in neuropathic pain states (see previous section). Nevertheless, there is still much to learn about the effects of this drug at the preclinical level. In fact, the analgesic effect of TTX in certain preclinical models that mimic highly prevalent painful neuropathies, such as diabetic neuropathy, has never been explored.

3.2. Preclinical Studies on Cancer Pain

Chronic cancer-related pain encompasses mixed pathophysiology as a consequence of tissue response to the primary tumor or metastases, and it can be considered a type of mixed nociceptive and neuropathic pain [74]. Although TTX has been used in several clinical trials to relieve cancer-related pain in patients (see next section), it is surprising that this drug is almost unexplored in preclinical models of pain induced by cancer, with only one article. Zhen and collaborators [71] evaluated the role of TTX in bone cancer pain. They found that sustained intrathecal injection of TTX (10 μg/kg, once a day) significantly attenuated mechanical allodynia and thermal hyperalgesia in rats with bone cancer.
With only one preclinical study, it seems clear that more research is needed to evaluate the effects of TTX in models of cancer-related pain.

This entry is adapted from the peer-reviewed paper 10.3390/toxins13070483


  1. Sá, K.N.; Moreira, L.; Baptista, A.F.; Yeng, L.T.; Teixeira, M.J.; Galhardoni, R.; de Andrade, D.C. Prevalence of chronic pain in developing countries: Systematic review and meta-analysis. Pain Rep. 2019, 4, e779.
  2. Jensen, T.S.; Baron, R.; Haanpää, M.; Kalso, E.; Loeser, J.D.; Rice, A.S.C.; Treede, R.D. A new definition of neuropathic pain. Pain 2011, 152, 2204–2205.
  3. Colloca, L.; Ludman, T.; Bouhassira, D.; Baron, R.; Dickenson, A.H.; Yarnitsky, D.; Freeman, R.; Truini, A.; Attal, N.; Finnerup, N.B.; et al. Neuropathic pain. Nat. Rev. Dis. Primers. 2017, 3, 17002.
  4. Watson, J.C.; Sandroni, P. Central Neuropathic Pain Syndromes. Mayo Clin. Proc. 2016, 91, 372–385.
  5. Costigan, M.; Scholz, J.; Woolf, C.J. Neuropathic pain: A maladaptive response of the nervous system to damage. Annu. Rev. Neurosci. 2009, 32, 1–32.
  6. Van Hecke, O.; Austin, S.K.; Khan, R.A.; Smith, B.H.; Torrance, N. Neuropathic pain in the general population: A systematic review of epidemiological studies. Pain 2014, 155, 654–662.
  7. Van den Beuken-van Everdingen, M.H.; Hochstenbach, L.M.; Joosten, E.A.; Tjan-Heijnen, V.C.; Janssen, D.J. Update on Prevalence of Pain in Patients with Cancer: Systematic Review and Meta-Analysis. J. Pain Symptom. Manag. 2016, 51, 1070–1090.
  8. Caraceni, A.; Shkodra, M. Cancer Pain Assessment and Classification. Cancers 2019, 11, 510.
  9. Finnerup, N.B.; Attal, N.; Haroutounian, S.; McNicol, E.; Baron, R.; Dworkin, R.H.; Gilron, I.; Haanpää, M.; Hansson, P.; Jensen, T.S.; et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol. 2015, 14, 162–173.
  10. Van den Beuken van Everdingen, M.H.J.; van Kuijk, S.M.J.; Janssen, D.J.A.; Joosten, E.A.J. Treatment of Pain in Cancer: Towards Personalised Medicine. Cancers 2018, 10, 502.
  11. Haumann, J.; Joosten, E.B.A.; Everdingen, M.H.J.V.D.B. Pain prevalence in cancer patients: Status quo or opportunities for improvement? Curr. Opin. Support Palliat. Care. 2017, 11, 99–104.
  12. Bates, D.; Schultheis, B.C.; Hanes, M.C.; Jolly, S.M.; Chakravarthy, K.V.; Deer, T.R.; Levy, R.M.; Hunter, C.W. A Comprehensive Algorithm for Management of Neuropathic Pain. Pain Med. 2019, 20 (Suppl. 1), S2–S12.
  13. Cooper, T.E.; Chen, J.; Wiffen, P.J.; Derry, S.; Carr, D.B.; Aldington, D.; Cole, P.; Moore, R.A. Morphine for chronic neuropathic pain in adults. Cochrane Database Syst. Rev. 2017, 5, CD011669.
  14. Van den Beuken-van Everdingen, M.H.; de Graeff, A.; Jongen, J.L.; Dijkstra, D.; Mostovaya, I.; Vissers, K.C.; National Guideline Working Group “Diagnosis Treatment of Cancer Pain”. Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review. Pain Pract. 2017, 17, 409–419.
  15. Cardoso, F.C.; Lewis, R.J. Sodium channels and pain: From toxins to therapies. Br. J. Pharmacol. 2018, 175, 2138–2157.
  16. Nieto, F.R.; Cobos, E.J.; Tejada, M.Á.; Sánchez-Fernández, C.; González-Cano, R.; Cendán, C.M. Tetrodotoxin (TTX) as a therapeutic agent for pain. Mar. Drugs 2012, 10, 281–305.
  17. De Lera Ruiz, M.; Kraus, R.L. Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications. J. Med. Chem. 2015, 58, 7093–7118.
  18. Fozzard, H.A.; Lipkind, G.M. The tetrodotoxin binding site is within the outer vestibule of the sodium channel. Mar. Drugs 2010, 8, 219–234.
  19. Latremoliere, A.; Woolf, C.J. Central sensitization: A generator of pain hypersensitivity by central neural plasticity. J. Pain 2009, 10, 895–926.
  20. Bennett, D.L.; Clark, A.J.; Huang, J.; Waxman, S.G.; Dib-Hajj, S.D. The Role of Voltage-Gated Sodium Channels in Pain Signaling. Physiol. Rev. 2019, 99, 1079–1151.
  21. Li, Y.; Zhang, X.; Fu, Z.; Zhou, Q. MicroRNA-212-3p Attenuates Neuropathic Pain via Targeting Sodium Voltage-gated Channel Alpha Subunit 3 (NaV 1.3). Curr. Neurovasc. Res. 2019, 16, 465–472.
  22. Cheng, K.I.; Wang, H.C.; Chuang, Y.T.; Chou, C.W.; Tu, H.P.; Yu, Y.C.; Chang, L.L.; Lai, C.S. Persistent mechanical allodynia positively correlates with an increase in activated microglia and increased P-p38 mitogen-activated protein kinase activation in streptozotocin-induced diabetic rats. Eur. J. Pain. 2014, 18, 162–173.
  23. Hong, S.; Morrow, T.J.; Paulson, P.E.; Isom, L.L.; Wiley, J.W. Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat. J. Biol. Chem. 2004, 279, 29341–29350.
  24. Berta, T.; Poirot, O.; Pertin, M.; Ji, R.R.; Kellenberger, S.; Decosterd, I. Transcriptional and functional profiles of voltage-gated Na(+) channels in injured and non-injured DRG neurons in the SNI model of neuropathic pain. Mol. Cell Neurosci. 2008, 37, 196–208.
  25. Casals-Díaz, L.; Casas, C.; Navarro, X. Changes of voltage-gated sodium channels in sensory nerve regeneration and neuropathic pain models. Restor. Neurol. Neurosci. 2015, 33, 321–334.
  26. Black, J.A.; Cummins, T.R.; Plumpton, C.; Chen, Y.H.; Hormuzdiar, W.; Clare, J.J.; Waxman, S.G. Upregulation of a silent sodium channel after peripheral, but not central, nerve injury in DRG neurons. J. Neurophysiol. 1999, 82, 2776–2785.
  27. Lin, C.R.; Chen, K.H.; Yang, C.H.; Huang, H.W.; Sheen-Chen, S.M. Intrathecal miR-183 delivery suppresses mechanical allodynia in mononeuropathic rats. Eur. J. Neurosci. 2014, 39, 1682–1689.
  28. Coward, K.; Aitken, A.; Powell, A.; Plumpton, C.; Birch, R.; Tate, S.; Bountra, C.; Anand, P. Plasticity of TTX-sensitive sodium channels PN1 and brain III in injured human nerves. Neuroreport 2001, 12, 495–500.
  29. Black, J.A.; Nikolajsen, L.; Kroner, K.; Jensen, T.S.; Waxman, S.G. Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann. Neurol. 2008, 64, 644–653.
  30. Liu, M.X.; Zhong, J.; Xia, L.; Dou, N.N.; Li, S.T. IL-6 contributes to Nav1.3 up-regulation in trigeminal nerve following chronic constriction injury. Neurol. Res. 2020, 42, 504–514.
  31. Liu, M.; Zhong, J.; Xia, L.; Dou, N.; Li, S. The expression of voltage-gated sodium channels in trigeminal nerve following chronic constriction injury in rats. Int. J. Neurosci. 2019, 129, 955–962.
  32. Yoon, J.H.; Son, J.Y.; Kim, M.J.; Kang, S.H.; Ju, J.S.; Bae, Y.C.; Ahn, D.K. Preemptive application of QX-314 attenuates trigeminal neuropathic mechanical allodynia in rats. Korean J. Physiol. Pharmacol. 2018, 22, 331–341.
  33. Aghdam, A.M.; Shahabi, P.; Karimi-Sales, E.; Ghiasi, R.; Sadigh-Eteghad, S.; Mahmoudi, J.; Alipour, M.R. Swimming Exercise Induced Reversed Expression of miR-96 and Its Target Gene NaV1.3 in Diabetic Peripheral Neuropathy in Rats. Chin. J. Physiol. 2018, 61, 124–129.
  34. Liu, J.; Wu, Y. Electro-acupuncture-modulated miR-214 prevents neuronal apoptosis by targeting Bax and inhibits sodium channel Nav1.3 expression in rats after spinal cord injury. Biomed. Pharmacother. 2017, 89, 1125–1135.
  35. Ren, Y.S.; Qian, N.S.; Tang, Y.; Liao, Y.H.; Yang, Y.L.; Dou, K.F.; Toi, M. Sodium channel Nav1.6 is up-regulated in the dorsal root ganglia in a mouse model of type 2 diabetes. Brain Res. Bull. 2012, 87, 244–249.
  36. Ding, H.H.; Zhang, S.B.; Lv, Y.Y.; Ma, C.; Liu, M.; Zhang, K.B.; Ruan, X.C.; Wei, J.Y.; Xin, W.J.; Wu, S.L. TNF-α/STAT3 pathway epigenetically upregulates Nav1.6 expression in DRG and contributes to neuropathic pain induced by L5-VRT. J. Neuroinflamm. 2019, 16, 29.
  37. Li, L.; Shao, J.; Wang, J.; Liu, Y.; Zhang, Y.; Zhang, M.; Zhang, J.; Ren, X.; Su, S.; Li, Y.; et al. MiR-30b-5p attenuates oxaliplatin-induced peripheral neuropathic pain through the voltage-gated sodium channel Nav1.6 in rats. Neuropharmacology 2019, 153, 111–120.
  38. Tseng, T.J.; Hsieh, Y.L.; Ko, M.H.; Hsieh, S.T. Redistribution of voltage-gated sodium channels after nerve decompression contributes to relieve neuropathic pain in chronic constriction injury. Brain Res. 2014, 1589, 15–25.
  39. Li, M.; Zhang, S.J.; Yang, L.; Fang, X.L.; Hu, H.F.; Zhao, M.Y.; Li, L.; Guo, Y.Y.; Shao, J.P. Voltage-gated sodium channel 1.7 expression decreases in dorsal root ganglia in a spinal nerve ligation neuropathic pain model. Kaohsiung J. Med. Sci. 2019, 35, 493–500.
  40. Jia, Q.; Dong, W.; Zhang, L.; Yang, X. Activating Sirt1 by resveratrol suppresses Nav1.7 expression in DRG through miR-182 and alleviates neuropathic pain in rats. Channels 2020, 14, 69–78.
  41. Tian, J.J.; Tan, C.Y.; Chen, Q.Y.; Zhou, Y.; Qu, Z.W.; Zhang, M.; Ma, K.T.; Shi, W.Y.; Li, L.; Si, J.Q. Upregulation of Nav1.7 by endogenous hydrogen sulfide contributes to maintenance of neuropathic pain. Int. J. Mol. Med. 2020, 46, 782–794.
  42. Li, Y.; North, R.Y.; Rhines, L.D.; Tatsui, C.E.; Rao, G.; Edwards, D.D.; Cassidy, R.M.; Harrison, D.S.; Johansson, C.A.; Zhang, H.; et al. DRG Voltage-Gated Sodium Channel 1.7 Is Upregulated in Paclitaxel-Induced Neuropathy in Rats and in Humans with Neuropathic Pain. J. Neurosci. 2018, 38, 1124–1136.
  43. Zhang, Q.; Martin-Caraballo, M.; Hsia, S.V. Modulation of Voltage-Gated Sodium Channel Activity in Human Dorsal Root Ganglion Neurons by Herpesvirus Quiescent Infection. J. Virol. 2020, 94, e01823-19.
  44. Yang, K.Y.; Kim, M.J.; Ju, J.S.; Park, S.K.; Lee, C.G.; Kim, S.T.; Bae, Y.C.; Ahn, D.K. Antinociceptive Effects of Botulinum Toxin Type A on Trigeminal Neuropathic Pain. J. Dent. Res. 2016, 95, 1183–1190.
  45. Stevens, A.M.; Liu, L.; Bertovich, D.; Janjic, J.M.; Pollock, J.A. Differential Expression of Neuroinflammatory mRNAs in the Rat Sciatic Nerve Following Chronic Constriction Injury and Pain-Relieving Nanoemulsion NSAID Delivery to Infiltrating Macrophages. Int. J. Mol. Sci. 2019, 20, 5269.
  46. Lindia, J.A.; Köhler, M.G.; Martin, W.J.; Abbadie, C. Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats. Pain 2005, 117, 145–153.
  47. Nassar, M.A.; Baker, M.D.; Levato, A.; Ingram, R.; Mallucci, G.; McMahon, S.B.; Wood, J.N. Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice. Mol. Pain 2006, 2, 33.
  48. Nassar, M.A.; Levato, A.; Stirling, L.C.; Wood, J.N. Neuropathic pain develops normally in mice lacking both Na(v)1.7 and Na(v)1.8. Mol. Pain 2005, 1, 24.
  49. Chang, W.; Berta, T.; Kim, Y.H.; Lee, S.; Lee, S.Y.; Ji, R.R. Expression and Role of Voltage-Gated Sodium Channels in Human Dorsal Root Ganglion Neurons with Special Focus on Nav1.7, Species Differences, and Regulation by Paclitaxel. Neurosci. Bull. 2018, 34, 4–12.
  50. Waxman, S.G.; Merkies, I.S.J.; Gerrits, M.M.; Dib-Hajj, S.D.; Lauria, G.; Cox, J.J.; Wood, J.N.; Woods, C.G.; Drenth, J.P.H.; Faber, C.G. Sodium channel genes in pain-related disorders: Phenotype-genotype associations and recommendations for clinical use. Lancet Neurol. 2014, 13, 1152–1160.
  51. Xie, W.; Strong, J.A.; Zhang, J.M. Local knockdown of the NaV1.6 sodium channel reduces pain behaviors, sensory neuron excitability, and sympathetic sprouting in rat models of neuropathic pain. Neuroscience 2015, 291, 317–330.
  52. Chen, L.; Huang, J.; Zhao, P.; Persson, A.K.; Dib-Hajj, F.B.; Cheng, X.; Tan, A.; Waxman, S.G.; Dib-Hajj, S.D. Conditional knockout of NaV1.6 in adult mice ameliorates neuropathic pain. Sci. Rep. 2018, 8, 3845.
  53. Waxman, S.G.; Dib-Hajj, S.; Cummins, T.R.; Black, J.A. Sodium channels and pain. Proc. Natl. Acad. Sci. USA 1999, 96, 7635–7639.
  54. Dib-Hajj, S.D.; Fjell, J.; Cummins, T.R.; Zheng, Z.; Fried, K.; LaMotte, R.; Black, J.A.; Waxman, S.G. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 1999, 83, 591–600.
  55. Leo, S.; D’Hooge, R.; Meert, T. Exploring the role of nociceptor-specific sodium channels in pain transmission using Nav1.8 and Nav1.9 knockout mice. Behav. Brain Res. 2010, 208, 149–157.
  56. Zimmer, T.; Haufe, V.; Blechschmidt, S. Voltage-gated sodium channels in the mammalian heart. Glob. Cardiol. Sci. Pract. 2014, 2014, 449–463.
  57. Marcil, J.; Walczak, J.S.; Guindon, J.; Ngoc, A.H.; Lu, S.; Beaulieu, P. Antinociceptive effects of tetrodotoxin (TTX) in rodents. Br. J. Anaesth. 2006, 96, 761–768.
  58. Hong, B.; He, J.; Sun, J.; Le, Q.; Bai, K.; Mou, Y.; Zhang, Y.; Chen, W.; Huang, W. Analgesia Effect of Enteric Sustained-Release Tetrodotoxin Pellets in the Rat. Pharmaceutics 2020, 12, 32.
  59. Alguacil, L.F.; Pérez-García, C.; Salas, E.; González-Martín, C.; Castillo, C.; Polanco, M.J.; Herradón, G.; Morales, L. Subcutaneous tetrodotoxin and inflammatory pain. Br. J. Anaesth. 2008, 100, 729–730.
  60. González-Cano, R.; Tejada, M.Á.; Artacho-Cordón, A.; Nieto, F.R.; Entrena, J.M.; Wood, J.N.; Cendán, C.M. Effects of Tetrodotoxin in Mouse Models of Visceral Pain. Mar. Drugs 2017, 15, 188.
  61. Xie, W.; Strong, J.A.; Meij, J.T.A.; Zhang, J.M.; Yu, L. Neuropathic pain: Early spontaneous afferent activity is the trigger. Pain 2005, 116, 243–256.
  62. Lyu, Y.S.; Park, S.K.; Chung, K.; Chung, J.M. Low dose of tetrodotoxin reduces neuropathic pain behaviors in an animal model. Brain Res. 2000, 871, 98–103.
  63. Chen, J.J.; Lue, J.H.; Lin, L.H.; Huang, C.T.; Chiang, R.P.; Chen, C.L.; Tsai, Y.J. Effects of pre-emptive drug treatment on astrocyte activation in the cuneate nucleus following rat median nerve injury. Pain 2010, 148, 158–166.
  64. Nozaki-Taguchi, N.; Chaplan, S.R.; Higuera, E.S.; Ajakwe, R.C.; Yaksh, T.L. Vincristine-induced allodynia in the rat. Pain 2001, 93, 69–76.
  65. Nieto, F.R.; Entrena, J.M.; Cendán, C.M.; Del Pozo, E.; Vela, J.M.; Baeyens, J.M. Tetrodotoxin inhibits the development and expression of neuropathic pain induced by paclitaxel in mice. Pain 2008, 137, 520–531.
  66. Entrena, J.M.; Cobos, E.J.; Nieto, F.R.; Cendán, C.M.; Gris, G.; Del Pozo, E.; Zamanillo, D.; Baeyens, J.M. Sigma-1 receptors are essential for capsaicin-induced mechanical hypersensitivity: Studies with selective sigma-1 ligands and sigma-1 knockout mice. Pain 2009, 143, 252–261.
  67. Kayser, V.; Viguier, F.; Ioannidi, M.; Bernard, J.F.; Latrémolière, A.; Michot, B.; Vela, J.M.; Buschmann, H.; Hamon, M.; Bourgoin, S. Differential anti-neuropathic pain effects of tetrodotoxin in sciatic nerve-versus infraorbital nerve-ligated rats—Behavioral, pharmacological and immunohistochemical investigations. Neuropharmacology 2010, 58, 474–487.
  68. Salas, M.M.; McIntyre, M.K.; Petz, L.N.; Korz, W.; Wong, D.; Clifford, J.L. Tetrodotoxin suppresses thermal hyperalgesia and mechanical allodynia in a rat full thickness thermal injury pain model. Neurosci. Lett. 2015, 607, 108–113.
  69. Hong, B.; Sun, J.; Zheng, H.; Le, Q.; Wang, C.; Bai, K.; He, J.; He, H.; Dong, Y. Effect of Tetrodotoxin Pellets in a Rat Model of Postherpetic Neuralgia. Mar. Drugs 2018, 16, 195.
  70. Alvarez, P.; Levine, J.D. Antihyperalgesic effect of tetrodotoxin in rat models of persistent muscle pain. Neuroscience 2015, 311, 499–507.
  71. Zheng, Q.; Fang, D.; Cai, J.; Wan, Y.; Han, J.S.; Xing, G.G. Enhanced excitability of small dorsal root ganglion neurons in rats with bone cancer pain. Mol. Pain 2018, 8, 24.
  72. Colvin, L.A. Chemotherapy-induced peripheral neuropathy: Where are we now? Pain 2019, 160 (Suppl. 1), S1–S10.
  73. Klein, T.; Magerl, W.; Rolke, R.; Treede, R.D. Human surrogate models of neuropathic pain. Pain 2005, 115, 227–233.
  74. Bennett, M.I.; Kaasa, S.; Barke, A.; Korwisi, B.; Rief, W.; Treede, R.D.; IASP Taskforce for the Classification of Chronic Pain. The IASP classification of chronic pain for ICD-11: Chronic cancer-related pain. Pain 2019, 160, 38–44.
This entry is offline, you can click here to edit this entry!
Video Production Service